WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 4 fonti

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

Raccontata daasia.nikkei.comfiercepharma.combenzinga.compharmaceutical-technology.com

Confronto fonti

4 prospettive sulla stessa storia
AI · summaries
pharmaceutical-technology.comStai leggendo1 mesi fa

Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.

originale

Timeline cronologica

  1. lunedì 18 maggio 2026·asia.nikkei.com

    Takeda found liable over antitrust plot to delay generic constipation drug

    Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

  2. martedì 19 maggio 2026·fiercepharma.com

    Takeda slapped with $885M verdict in pay-for-delay antitrust case

    Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure…

fiercepharma.com
1 mesi fa

Takeda slapped with $885M verdict in pay-for-delay antitrust case

Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure that could be roug | Takeda plans to…

Leggi questa versione → originale
benzinga.com1 mesi fa

Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)

Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.

Leggi questa versione → originale
asia.nikkei.com1 mesi fa

Takeda found liable over antitrust plot to delay generic constipation drug

Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme

Leggi questa versione → originale
  • martedì 19 maggio 2026·benzinga.com

    Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)

    Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.

  • mercoledì 20 maggio 2026·pharmaceutical-technology.com

    Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology

    Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.